drugset
drugset / Trial / NCT02403128

Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery Macroaneurysms

NCT02403128 ↗

Phase 1 Unknown 6 enrolled Kamal Kishore, MD
NaSingle-groupOpen-labelTreatment

Summary

Phase 1, non-randomized, open label, noncomparative trial to study the effect of intravitreal injection of aflibercept on eyes with symptomatic macular edema from retinal artery macroaneurysms.

Timeline

Start
2015-05-14
Primary completion
2020-02
Completion
2020-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal

Indications

macular retinal edema retinal vascular disorder